Skip to main content
    S

    Sunshine Biopharma Inc (SBFM)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $2.60
    -0.10 (-3.70%)

    Market Cap: $2.22M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Sunshine Biopharma Inc (SBFM) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Sunshine Biopharma (SBFM) to earn -$39.00 per share in the fiscal year ending Dec 31, 2026, on revenue of $36.75M. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down. For the fiscal year ending Dec 31, 2027, the EPS consensus is -$8.00.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 22.4%.

    Fiscal year ending Dec 31, 2026
    -$39.00
    EPS consensus, revenue $36.75M
    Fiscal year ending Dec 31, 2027
    -$8.00
    EPS consensus, revenue $45.00M
    Next report
    Apr 1, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$39.00-$39.00 to -$39.001$36.75M$36.75M to $36.75M1
    Dec 31, 2027-$8.00-$8.00 to -$8.001$45.00M$45.00M to $45.00M1

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$5.92N/A3$10.00M$9.60M to $10.29M3

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 1 upward and 1 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202701

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$126.00.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$39.00-$126.00-$126.00-$126.00-$126.00N/A
    Fiscal year ending Dec 31, 2027-$8.00$4.00$4.00$4.00$4.00N/A

    Frequently Asked Questions About SBFM

    What is the SBFM stock forecast?

    Consensus analyst estimates put Sunshine Biopharma's EPS at -$39.00 for the fiscal year ending Dec 31, 2026, on revenue of $36.75M.

    What EPS do analysts expect from SBFM next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$39.00, with estimates from -$39.00 to -$39.00 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$8.00, with estimates from -$8.00 to -$8.00 from 1 analyst.

    What revenue do analysts expect from Sunshine Biopharma next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $36.75M, with estimates from $36.75M to $36.75M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $45.00M, with estimates from $45.00M to $45.00M.

    How many analysts cover SBFM?

    1 analyst estimates EPS for Sunshine Biopharma for the fiscal year ending Dec 31, 2026.